Compare AMTD & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AMTD | RFL |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 69.7M |
| IPO Year | 2019 | 2017 |
| Metric | AMTD | RFL |
|---|---|---|
| Price | $0.98 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.6K | ★ 65.5K |
| Earning Date | 04-29-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.87 | $1.12 |
| 52 Week High | $1.65 | $3.19 |
| Indicator | AMTD | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.56 | 58.98 |
| Support Level | $0.96 | $1.28 |
| Resistance Level | $1.07 | $1.59 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.64 | 78.57 |
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.